From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of lightchain amyloidosis .
LC kinetic stabilizer-1 (compound 21) is a potent and selective amyloidogenic immunoglobulin lightchain kinetic stabilizer with EC50s of 140 and 74.1 nM for WIL-FL * and WIL-FL * T46L/F49Y, respectively. WIL-FL is an amyloidogenic FL LC dimer .
W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin lightchain kinase with IC50 values of 28 μM and 51 µM, respectively . W-7 hydrochloride induces apoptosis and has antitumor activity .
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa lightchains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard lightchain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .
MLCK inhibitor peptide 18 is a myosin lightchain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca 2+ release .
Dilauryl thiodipropionate (DLTDP), which is a sulfur-containing antioxidant commonly used to stabilize polymers and plastics against degradation caused by heat, oxygen, and UV light, acts to scavenge free radicals and others that may cause polymer chain scission and cross-linked active substances, in addition, DLTDP has been used as an additive to lubricants, oils and other industrial fluids to improve their oxidation stability, the long hydrocarbon chain in DLTDP makes it low volatility and compatible with many materials and Good compatibility with substrates.
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and lightchains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin lightchain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively .
ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin lightchain) . OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner . OSU-T315 causes cell death through apoptosis and autophagy .
Dilauryl thiodipropionate (DLTDP), which is a sulfur-containing antioxidant commonly used to stabilize polymers and plastics against degradation caused by heat, oxygen, and UV light, acts to scavenge free radicals and others that may cause polymer chain scission and cross-linked active substances, in addition, DLTDP has been used as an additive to lubricants, oils and other industrial fluids to improve their oxidation stability, the long hydrocarbon chain in DLTDP makes it low volatility and compatible with many materials and Good compatibility with substrates.
MLCK inhibitor peptide 18 is a myosin lightchain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
Myosin lightchain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin lightchain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca 2+ entry. Myosin lightchain kinase fragment 11-19 amide can be used in the research of human cervical cancer .
Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard lightchain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .
MLCK Peptide, control is a myosin light-chain
kinase. Adding MLCK peptide to permeabilized L15 cells dramatically decreased
IICR. MLCK peptide caused a reduction in the extent of IICR with no change in
the affinity of IP3 for the IP3R .
Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca 2+ release .
MCE Protein L Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein L, effectively purifies mammalian monoclonal and polyclonal antibodies which have kappa lightchain.
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of lightchain amyloidosis .
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa lightchains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis .
Anti-Mouse Kappa Immunoglobulin LightChain Antibody (HB-58) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse Kappa Immunoglobulin LightChain.
Anti-Rat Kappa Immunoglobulin LightChain Antibody (MAR 18.5) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to rat Kappa Immunoglobulin LightChain.
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and lightchains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
Ferritin light chain/FTL protein is pivotal in iron homeostasis, storing iron in a soluble, non-toxic form and delivering it to cells. In kidney development, FTL mediates iron uptake in capsule cells, crucial for organogenesis. Structurally, FTL, an oligomer with light and heavy subunits forming a spherical shell, facilitates iron entry through pores. Mutations in the C-terminus disrupt pore formation, impacting iron accumulation. Ferritin light chain/FTL Protein, Human (His) is the recombinant human-derived Ferritin light chain/FTL protein, expressed by E. coli , with N-6*His labeled tag. The total length of Ferritin light chain/FTL Protein, Human (His) is 175 a.a., with molecular weight of 20-25 kDa.
PIN/DYNLL1 acts as a non-catalytic accessory component in the cytoplasmic dynein 1 complex, connecting dynein to cargos and adapter proteins for dynein modulation. It functions as a motor for retrograde vesicle movement along microtubules, potentially influencing cytoskeletal structure. PIN/DYNLL1 enhances ESR1 transactivation and aids ESR1 nuclear localization. PIN/DYNLL1 Protein, Human (His) is the recombinant human-derived PIN/DYNLL1 protein, expressed by E. coli, with N-6*His labeled tag. The total length of PIN/DYNLL1 Protein, Human (His) is 89 a.a., with molecular weight of ~14.0 kDa.
The KLC2 protein is a key kinesin-1 complex component that is essential for the generation of microtubule-associated forces and organelle transport. Its light chain facilitates the coupling of cargo to the heavy chain and regulates ATPase activity. KLC2 Protein, Human (sf9, His-GST) is the recombinant human-derived KLC2 protein, expressed by Sf9 insect cells , with C-His, N-GST labeled tag. The total length of KLC2 Protein, Human (sf9, His-GST) is 622 a.a., with molecular weight of ~96.8 KDa.
MAP1LC3B is a key ubiquitin-like modifier essential for the formation of autophagosome vacuoles, which maintains cellular homeostasis. In mitophagy, it regulates mitochondrial number, suppresses reactive oxygen species and ensures energy efficiency. MAP1LC3B Protein, Human is the recombinant human-derived MAP1LC3B protein, expressed by E. coli , with tag free. The total length of MAP1LC3B Protein, Human is 125 a.a., with molecular weight of ~16.15 kDa.
MAP1LC3A is a key ubiquitin-like modifier essential for autophagosome vacuole formation, ensuring cellular homeostasis. As part of the GABARAP/GATE-16 subfamily, it plays a crucial role in late autophagosome maturation. MAP1LC3A Protein, Human (His) is the recombinant human-derived MAP1LC3A protein, expressed by E. coli , with C-6*His labeled tag. The total length of MAP1LC3A Protein, Human (His) is 121 a.a., with molecular weight of ~16.0 kDa.
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (His) is the recombinant pig-derived Coagulation Factor XII/F12 protein, expressed by E. coli , with N-6*His labeled tag. The total length of Coagulation Factor XII/F12 Protein, Pig (His) is 352 a.a., with molecular weight of ~43.8 kDa.
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. F12/Coagulation Factor XII, Pig (P. pastoris, His) is the recombinant pig-derived F12/Coagulation Factor XII, Pig, expressed by P. pastoris , with N-6*His labeled tag. The total length of F12/Coagulation Factor XII, Pig (P. pastoris, His) is 352 a.a., with molecular weight of 41.8 kDa.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor XI/F11 protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor XI/F11 Protein, Human (HEK293, His) is 625 a.a., with molecular weight of 75-80 kDa.
Factor IX (F9) is a vitamin K-dependent plasma protein that plays a critical role in the intrinsic pathway of coagulation. Factor IX coordinates the conversion of factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. Coagulation factor IX/F9 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor IX/F9 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Coagulation factor IX/F9 Protein, Human (HEK293, His) is 433 a.a., with molecular weight of 60-90 kDa.
S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (C-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with C-6*His labeled tag. The total length of S100A8 Protein, Human (C-His) is 93 a.a., with molecular weight of ~13.0 kDa.
S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (N-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with N-6*His labeled tag. The total length of S100A8 Protein, Human (N-His) is 93 a.a., with molecular weight of ~12 kDa.
S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (sf9, His) is the recombinant human-derived S100A8 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of S100A8 Protein, Human (sf9, His) is 93 a.a., with molecular weight of ~14.6 kDa.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Human (His) is the recombinant human-derived Coagulation Factor XI/F11 protein, expressed by E. coli , with N-6*His labeled tag. The total length of Coagulation Factor XI/F11 Protein, Human (His) is 369 a.a., with molecular weight of ~45.2 kDa.
S100A8 protein functions as a danger signal in inflammation, activating innate immune cells by binding to receptors like Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). This triggers signaling pathways that enhance the pro-inflammatory response. S100A8 Protein, Rat (His) is the recombinant rat-derived S100A8 protein, expressed by E. coli , with C-6*His labeled tag. The total length of S100A8 Protein, Rat (His) is 89 a.a., with molecular weight of ~13.0 kDa.
Myosin Light Chain 2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 19 kDa, targeting to Myosin Light Chain 2. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.
Myosin light chain kinase Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 211 kDa, targeting to Myosin light chain kinase. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.
LC3 Antibody is an unconjugated, approximately 14/16 kDa, rabbit-derived, anti-LC3 polyclonal antibody. LC3 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, rat, and predicted: mouse, chicken, dog, pig, cow, horse, sheep, goat background without labeling.
SLC7A5; CD98LC, LAT1; MPE16; Large neutral amino acids transporter small subunit 1; 4F2 lightchain (4F2 LC; 4F2LC); CD98 lightchain; Integral membrane protein E16; Solute carrier family 7 member 5
